{"DataElement":{"publicId":"7093658","version":"1","preferredName":"London Deauville Criteria Point Scale Base Upon Exclusion Fludeoxyglucose F-18 Avidity Non-Lymphoma Lesion Outcome FDG-Positron Emission Tomography Score","preferredDefinition":"The Deauville score related to a 5 point scale devised to assess the response to treatment of Hodgkin and Aggressive Non-Hodgkin Lymphoma based on excluding FDG avid non-lymphoma lesion.","longName":"6774576v1.0:4643013v1.0","context":"Alliance","contextVersion":"1","DataElementConcept":{"publicId":"6774576","version":"1","preferredName":"London Deauville Criteria Point Scale Base Upon Exclusion Fludeoxyglucose F-18 Avidity Negation Lymphoma Lesion Outcome","preferredDefinition":"A 5 point scale devised to assess the response to treatment of Hodgkin and Aggressive Non-Hodgkin Lymphoma._The most important or necessary part of something._Used to indicate that an event is to immediately follow another event._The deliberate act of omission._A positron-emitting radiopharmaceutical containing radioactive 2-deoxy-2-[18F] fluoro-D-glucose. With similar cell uptake as glucose (high in tumor cells), fludeoxyglucose F 18 is not dephosphorylated and further metabolized. (NCI04)_Strength of binding, usually of a small molecule with multiple binding sites by a larger, particularly the binding of a complex antigen by an antibody._An operation in which a term denies or inverts the meaning of another term or construction._A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas._A localized pathological or traumatic structural change, damage, deformity, or discontinuity of tissue, organ, or body part._The result of an action.","longName":"6774573v1.0:6774574v1.0","context":"Alliance","contextVersion":"1","ObjectClass":{"publicId":"6774573","version":"1","preferredName":"London Deauville Criteria Point Scale","preferredDefinition":"A 5 point scale devised to assess the response to treatment of Hodgkin and Aggressive Non-Hodgkin Lymphoma.","longName":"C99723","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"London Deauville Criteria Point Scale","conceptCode":"C99723","definition":"A 5 point scale devised to assess the response to treatment of Hodgkin and Aggressive Non-Hodgkin Lymphoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8A828489-DCC0-559D-E053-F662850AFBCA","latestVersionIndicator":"Yes","beginDate":"2019-06-04","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-06-04","modifiedBy":"ONEDATA","dateModified":"2019-06-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"6774574","version":"1","preferredName":"Base Upon Exclusion Fludeoxyglucose F-18 Avidity Negation Lymphoma Lesion Outcome","preferredDefinition":"The most important or necessary part of something.:Used to indicate that an event is to immediately follow another event.:The deliberate act of omission.:The radioactive form of glucose used in positron emission tomography (PET), a diagnostic imaging procedure.:Strength of binding, usually of a small molecule with multiple binding sites by a larger, particularly the binding of a complex antigen by an antibody.:An operation in which a term denies or inverts the meaning of another term or construction.:A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas.:A localized pathological or traumatic structural change, damage, deformity, or discontinuity of tissue, organ, or body part.:The result of an action.","longName":"6774574v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Base","conceptCode":"C48055","definition":"The most important or necessary part of something.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"8"},{"longName":"Upon","conceptCode":"C65137","definition":"Used to indicate that an event is to immediately follow another event.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"7"},{"longName":"Exclusion","conceptCode":"C82931","definition":"The deliberate act of omission.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"6"},{"longName":"Fludeoxyglucose F-18","conceptCode":"C964","definition":"A positron-emitting radiopharmaceutical containing radioactive 2-deoxy-2-[18F] fluoro-D-glucose. With similar cell uptake as glucose (high in tumor cells), fludeoxyglucose F 18 is not dephosphorylated and further metabolized. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"5"},{"longName":"Avidity","conceptCode":"C16297","definition":"Strength of binding, usually of a small molecule with multiple binding sites by a larger, particularly the binding of a complex antigen by an antibody.","evsSource":"CTCAE_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Negation","conceptCode":"C25594","definition":"An operation in which a term denies or inverts the meaning of another term or construction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Lymphoma","conceptCode":"C3208","definition":"A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Lesion","conceptCode":"C3824","definition":"A localized pathological or traumatic structural change, damage, deformity, or discontinuity of tissue, organ, or body part.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Outcome","conceptCode":"C20200","definition":"The result of an action.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8A828489-DCD8-559D-E053-F662850AFBCA","latestVersionIndicator":"Yes","beginDate":"2019-06-04","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-06-04","modifiedBy":"ONEDATA","dateModified":"2019-06-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2233241","version":"1","preferredName":"Medical Imaging","preferredDefinition":"Events, people, materials and activities uniquely defined by medical imaging.  ","longName":"MEDICAL IMAGING","context":"CIP","contextVersion":"2.31","origin":"DICOM:Digital Imaging and Communications in Medicine","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F96173D7-A9B4-3CBB-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-12","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-06-12","modifiedBy":"SBREXT","dateModified":"2006-09-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"Alliance Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8A828489-DCE9-559D-E053-F662850AFBCA","latestVersionIndicator":"Yes","beginDate":"2019-06-04","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-06-04","modifiedBy":"MORENOC","dateModified":"2019-11-07","changeDescription":"11/7/2019: CM Released as part of draft content review","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"4643013","version":"1","preferredName":"FDG-Positron Emission Tomography Score","preferredDefinition":"Deauville score grades - from 1 to 5 with the score of 1 meaning no uptake consistent with lymphoma, up to 5 which means a dramatic increase in uptake and/or new sites of involvement.","longName":"PETScr","context":"COG","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"1","maxLength":"10","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Score 5","valueDescription":"Score 5: Markedly increased uptake > normal liver.","ValueMeaning":{"publicId":"5121680","version":"1","preferredName":"Score 5: Markedly increased uptake > normal liver.","longName":"5121680","preferredDefinition":"Score 5: Markedly increased uptake > normal liver.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2B744C11-A49D-E33C-E050-BB89AD4358D7","latestVersionIndicator":"Yes","beginDate":"2016-02-10","endDate":null,"createdBy":"WONGW","dateCreated":"2016-02-10","modifiedBy":"KUMMEROA","dateModified":"2023-04-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2B744C11-A4B6-E33C-E050-BB89AD4358D7","beginDate":"2014-12-22","endDate":null,"createdBy":"WONGW","dateCreated":"2016-02-10","modifiedBy":"ONEDATA","dateModified":"2016-02-10","deletedIndicator":"No"},{"value":"Score 1","valueDescription":"Score 1: No uptake.","ValueMeaning":{"publicId":"5121671","version":"1","preferredName":"Score 1: No uptake.","longName":"5121671","preferredDefinition":"Score 1: No uptake.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2B744C11-A384-E33C-E050-BB89AD4358D7","latestVersionIndicator":"Yes","beginDate":"2016-02-10","endDate":null,"createdBy":"WONGW","dateCreated":"2016-02-10","modifiedBy":"KUMMEROA","dateModified":"2023-04-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2B744C11-A39D-E33C-E050-BB89AD4358D7","beginDate":"2014-12-22","endDate":null,"createdBy":"WONGW","dateCreated":"2016-02-10","modifiedBy":"ONEDATA","dateModified":"2016-02-10","deletedIndicator":"No"},{"value":"Score 2","valueDescription":"Score 2: Uptake <= mediastinal blood pool.","ValueMeaning":{"publicId":"5121678","version":"1","preferredName":"Score 2: Uptake <= mediastinal blood pool.","longName":"5121678","preferredDefinition":"Score 2: Uptake <= mediastinal blood pool.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2B744C11-A457-E33C-E050-BB89AD4358D7","latestVersionIndicator":"Yes","beginDate":"2016-02-10","endDate":null,"createdBy":"WONGW","dateCreated":"2016-02-10","modifiedBy":"KUMMEROA","dateModified":"2023-04-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2B744C11-A470-E33C-E050-BB89AD4358D7","beginDate":"2014-12-22","endDate":null,"createdBy":"WONGW","dateCreated":"2016-02-10","modifiedBy":"ONEDATA","dateModified":"2016-02-10","deletedIndicator":"No"},{"value":"Score 3","valueDescription":"Score 3: Uptake > mediastinal blood pool and <= normal liver.","ValueMeaning":{"publicId":"5121679","version":"1","preferredName":"Score 3: Uptake > mediastinal blood pool and <= normal liver.","longName":"5121679","preferredDefinition":"Score 3: Uptake > mediastinal blood pool and <= normal liver.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2B744C11-A47A-E33C-E050-BB89AD4358D7","latestVersionIndicator":"Yes","beginDate":"2016-02-10","endDate":null,"createdBy":"WONGW","dateCreated":"2016-02-10","modifiedBy":"KUMMEROA","dateModified":"2023-04-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2B744C11-A493-E33C-E050-BB89AD4358D7","beginDate":"2014-12-22","endDate":null,"createdBy":"WONGW","dateCreated":"2016-02-10","modifiedBy":"ONEDATA","dateModified":"2016-02-10","deletedIndicator":"No"},{"value":"Score 4","valueDescription":"Score 4: Moderately increased uptake > normal liver.","ValueMeaning":{"publicId":"5121674","version":"1","preferredName":"Score 4: Moderately increased uptake > normal liver.","longName":"5121674","preferredDefinition":"Score 4: Moderately increased uptake > normal liver.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2B744C11-A3ED-E33C-E050-BB89AD4358D7","latestVersionIndicator":"Yes","beginDate":"2016-02-10","endDate":null,"createdBy":"WONGW","dateCreated":"2016-02-10","modifiedBy":"KUMMEROA","dateModified":"2023-04-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2B744C11-A406-E33C-E050-BB89AD4358D7","beginDate":"2014-12-22","endDate":null,"createdBy":"WONGW","dateCreated":"2016-02-10","modifiedBy":"ONEDATA","dateModified":"2016-02-10","deletedIndicator":"No"},{"value":"Score X","valueDescription":"Score X: New areas of uptake unlikely to be related to lymphoma","ValueMeaning":{"publicId":"5337087","version":"1","preferredName":"Score X: New areas of uptake unlikely to be related to lymphoma","longName":"5337087","preferredDefinition":"Score X: New areas of uptake unlikely to be related to lymphoma","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"36FA2A25-1179-BFAC-E050-BB89AD430986","latestVersionIndicator":"Yes","beginDate":"2016-07-06","endDate":null,"createdBy":"WONGW","dateCreated":"2016-07-06","modifiedBy":"KUMMEROA","dateModified":"2023-04-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"36FA2A25-1192-BFAC-E050-BB89AD430986","beginDate":"2016-07-06","endDate":null,"createdBy":"WONGW","dateCreated":"2016-07-06","modifiedBy":"ONEDATA","dateModified":"2016-07-06","deletedIndicator":"No"},{"value":"Not done","valueDescription":"Not Done","ValueMeaning":{"publicId":"4163021","version":"1","preferredName":"Not Done","longName":"4163021","preferredDefinition":"Indicates a task, process or examination that has either not been initiated or not been completed.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Done","conceptCode":"C49484","definition":"Indicates a task, process or examination that has either not been initiated or not been completed.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F2B5E544-9A39-F7D4-E040-BB89AD4312F7","latestVersionIndicator":"Yes","beginDate":"2014-02-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-02-18","modifiedBy":"KUMMEROA","dateModified":"2023-12-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2BD746E8-0D81-7D65-E050-BB89AD430684","beginDate":"2016-02-15","endDate":null,"createdBy":"ZIEGLERK","dateCreated":"2016-02-15","modifiedBy":"ONEDATA","dateModified":"2016-02-15","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"4643012","version":"1","preferredName":"FDG-Positron Emission Tomography Scale Score","preferredDefinition":"An imaging technique that utilizes positron emission tomography to produce a three-dimensional image of functional processes in the body. The system detects pairs of gamma rays emitted indirectly by a positron-emitting radionuclide (tracer), which is introduced into the body on the biologically active molecule (fludeoxyglucose) FDG. FDG is an analogue of glucose which when imaged will give tissue metabolic activity, in terms of regional glucose uptake.:an ordered reference standard.:A number or range of numeric values measuring performance, function, quality, or ability.","longName":"C103400:C25664:C25338","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"FDG-Positron Emission Tomography","conceptCode":"C103400","definition":"An imaging technique that utilizes positron emission tomography to produce a three-dimensional image of functional processes in the body. The system detects pairs of gamma rays emitted indirectly by a positron-emitting radionuclide (tracer), which is introduced into the body on the biologically active molecule (fludeoxyglucose) FDG. FDG is an analogue of glucose which when imaged will give tissue metabolic activity, in terms of regional glucose uptake.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Scale","conceptCode":"C25664","definition":"An ordered reference standard used to measure incremental changes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Score","conceptCode":"C25338","definition":"A number or range of numeric values measuring performance, function, quality, or ability.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0AD3EB03-038C-700F-E050-BB89AD43129A","latestVersionIndicator":"Yes","beginDate":"2014-12-22","endDate":null,"createdBy":"CORRALC","dateCreated":"2014-12-22","modifiedBy":"ONEDATA","dateModified":"2014-12-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0AD3EB03-039D-700F-E050-BB89AD43129A","latestVersionIndicator":"Yes","beginDate":"2014-12-22","endDate":null,"createdBy":"CORRALC","dateCreated":"2014-12-22","modifiedBy":"HLAINGY","dateModified":"2016-10-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"Deauville score based on excl","type":"Preferred Question Text","description":"Deauville score based on excluding FDG avid non-lymphoma lesion","url":null,"context":"Alliance"}],"origin":"Alliance Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"99D73CB0-A03F-72F4-E053-F662850AFEDE","latestVersionIndicator":"Yes","beginDate":"2019-12-17","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-12-17","modifiedBy":"MORENOC","dateModified":"2020-03-25","changeDescription":"3/25/2020: CM Released as part of draft content review","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}